Female Sexual Function Index (FSFI)

1. Abstract

The Female Sexual Function Index (FSFI) is an internationally recognized, gold-standard, self-report psychometric instrument designed to assess multidimensional aspects of female sexual functioning over a 4-week recall period. Developed by Raymond Rosen and an expert consensus panel in 2000, the FSFI was engineered in response to the clinical and pharmacological need for a validated, brief, and psychometrically robust measurement tool to quantify female sexual dysfunction (FSD) in clinical trials and epidemiological research. The instrument consists of 19 items organized into six distinct clinical domains: Sexual Desire (2 items), Sexual Arousal (4 items), Lubrication (4 items), Orgasm (3 items), Sexual Satisfaction (3 items), and Pain (3 items). Responses are captured using differentiated 5-point and 6-point Likert-type scales, with items relating to partnered or coital activities offering an explicit score of zero to denote sexual inactivity. Domain scores are derived by summing raw item scores within each dimension and multiplying by predetermined domain-specific factor weights (0.6 for desire; 0.3 for arousal and lubrication; 0.4 for orgasm, satisfaction, and pain), yielding domain scores ranging from 0 (or 1.2 for desire) to 6.0, and a composite full-scale score ranging from 2.0 to 36.0.

Extensive psychometric evaluations have demonstrated that the FSFI possesses exceptional internal consistency reliability (Cronbach’s alpha values ranging from 0.82 to 0.97 across subscales and exceeding 0.95 for the total scale) and high test-retest reliability across 2- to 4-week intervals (Pearson correlation coefficients ranging from r = 0.79 to 0.88). Confirmatory factor analyses (CFA) across diverse international populations have robustly substantiated the six-factor structural model, which aligns with diagnostic frameworks delineated in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR and DSM-5). A total score cutoff of 26.55 established by Wiegel, Meston, and Rosen (2005) provides optimal diagnostic sensitivity (77% to 88%) and specificity (78% to 89%) for distinguishing women with clinical sexual dysfunction from sexually functional controls. This article provides an exhaustive psychometric, theoretical, structural, and administrative profile of the FSFI, reviewing its measurement properties, construct validity, clinical utility, scoring algorithms, and cultural adaptations.

2. Keywords

Female Sexual Function Index, FSFI, female sexual dysfunction, hypoactive sexual desire disorder, female sexual arousal disorder, dyspareunia, psychometrics, sexual satisfaction, sexual health measurement, clinical cutoff score, factor analysis, construct validity

3. Authors

The Female Sexual Function Index was formulated and standardized by a multidisciplinary consortium of clinical psychologists, urologists, psychometricians, and gynecological researchers specializing in human sexuality. The original validation study, published in the Journal of Sex & Marital Therapy in 2000, was authored by:

• Raymond C. Rosen, Ph.D. — Department of Psychiatry, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey (UMDNJ), Piscataway, NJ, USA. (Principal Investigator).
• Cathy Brown, M.S. — Department of Psychiatry, Robert Wood Johnson Medical School, Piscataway, NJ, USA.
• Julia R. Heiman, Ph.D. — Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, USA (later The Kinsey Institute for Research in Sex, Gender, and Reproduction, Indiana University).
• Sandra R. Leiblum, Ph.D. — Department of Psychiatry, Robert Wood Johnson Medical School, Piscataway, NJ, USA.
• Cindy M. Meston, Ph.D. — Department of Psychology, University of Texas at Austin, Austin, TX, USA.
• Ridwan Shabsigh, M.D. — Department of Urology, Columbia University College of Physicians and Surgeons, New York, NY, USA.
• DeWayne Ferguson, Ph.D. — Statistics and Data Management, Clinical Development, Pfizer Inc., New York, NY, USA.
• Ralph B. D’Agostino Jr., Ph.D. — Department of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC, USA.

Corresponding academic communications regarding the original development of the FSFI were historically coordinated via Dr. Raymond C. Rosen at the Department of Psychiatry, Robert Wood Johnson Medical School, 675 Hoes Lane, Piscataway, NJ 08854, USA.

4. Purpose

The primary purpose of the Female Sexual Function Index is to provide a brief, multidimensional, scientifically rigorous, self-administered psychometric tool capable of assessing key dimensions of sexual function in women within clinical trials, clinical practice, and behavioral research. Historically, the clinical assessment of female sexual function was characterized by fragmented, non-standardized inventories, many of which lacked systematic psychometric validation, failed to reflect consensus diagnostic criteria, or imposed an excessive administrative burden on patients. With the emergence of targeted pharmacotherapies, hormonal interventions, and psychotherapeutic modalities for female sexual health in the late 1990s, the development of a standardized metric became an international medical necessity.

The FSFI was specifically developed to measure the major behavioral, physiological, and affective components of female sexual function across a 4-week recall window. It serves three main functions across clinical and empirical contexts:

• Diagnostic Screening and Clinical Profiling: In outpatient gynecology, psychiatry, and sex therapy clinics, the FSFI allows clinicians to rapidly screen for sexual difficulties, differentiate generalized from domain-specific complaints (e.g., distinguishing primary desire deficiency from secondary arousal failure or penetrative pain), and establish baseline symptom severity before initiating treatment.
• Outcome Measurement in Clinical Trials: The FSFI was engineered to meet the stringent empirical requirements established by international regulatory agencies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), for primary and secondary endpoints in phase II, III, and IV clinical trials investigating pharmacologic, surgical, and psychological treatments for female sexual dysfunction.
• Epidemiological and Health Research: The scale enables researchers to assess the prevalence, incidence, and biopsychosocial correlates of female sexual dysfunction across diverse populations, such as women undergoing menopause, oncological treatments, postpartum transitions, or living with chronic endocrine, neurological, or cardiovascular illnesses.

Importantly, the FSFI was designed to capture functioning along a continuum, allowing for the measurement of both severe pathology and high sexual well-being, while maintaining operational sensitivity to therapeutic change over time.

5. Psychological Construct

The FSFI operationalizes female sexual functioning as a complex, multifaceted biopsychosocial construct comprised of six interrelated yet empirically distinguishable dimensions. These dimensions map directly onto both physiological responses and psychological experiences of female sexual interactions:

5.1. Sexual Desire (Items 1 and 2)

The Desire domain assesses the subjective, psychological component of sexual motivation, libido, and sexual drive. It captures both internal cognitive-affective manifestations (such as spontaneous sexual fantasies, mental imagery, and longing for sexual expression) and receptive sexual interest (the willingness to respond to a partner’s sexual initiations). Item 1 quantifies the frequency of desire over the preceding 4 weeks, whereas Item 2 evaluates the intensity or magnitude of the desire state. In clinical nosology, impairment in this construct corresponds to Hypoactive Sexual Desire Disorder (HSDD) or the desire-component of Female Sexual Interest/Arousal Disorder (FSIAD).

5.2. Sexual Arousal (Items 3, 4, 5, and 6)

The Arousal domain measures the psychological, central-nervous-system-mediated sense of sexual excitement (“feeling turned on”) during sexual activity or coitus. Rather than focusing exclusively on peripheral autonomic markers, this domain operationalizes arousal as a dynamic construct encompassing frequency of excitement (Item 3), perceived magnitude or level of arousal (Item 4), self-efficacy and confidence in one’s capacity to achieve arousal (Item 5), and subjective satisfaction with the overall arousal experience (Item 6). This multi-item structure reflects the clinical reality that women can experience subjective cognitive arousal even in the absence of complete peripheral physiological congruence.

5.3. Lubrication (Items 7, 8, 9, and 10)

The Lubrication domain isolates the peripheral, neurovascular, and pelvic physiological response to sexual stimulation. Vasocongestion of the vaginal wall tissues leads to transudation of plasma-like fluid through the vaginal epithelium, producing lubrication. This domain evaluates four critical facets of this process: the frequency of becoming lubricated (Item 7), the difficulty experienced in achieving lubrication (Item 8), the ability to sustain lubrication until the completion of sexual activity (Item 9), and the difficulty encountered in maintaining such lubrication (Item 10). Deficits in this domain are biologically indicative of autonomic dysregulation, local epithelial atrophy, or hypoestrogenic states (such as those observed in the genitourinary syndrome of menopause).

5.4. Orgasm (Items 11, 12, and 13)

The Orgasm domain evaluates the climax or peak phase of sexual response, marked by rhythmic neuromuscular contractions of the pelvic floor and intense affective release. The three items evaluate the frequency of reaching orgasm during sexual stimulation or intercourse (Item 11), the subjective difficulty in achieving climax (Item 12), and the level of satisfaction with one’s orgasmic capacity (Item 13). This domain distinguishes orgasmic infrequency from orgasmic distress or delay, operationalizing clinical criteria for Female Orgasmic Disorder.

5.5. Sexual Satisfaction (Items 14, 15, and 16)

The Satisfaction domain measures the evaluative and affective appraisal of the individual’s sexual experiences and relational dynamics. Recognizing that sexual well-being is not reducible to mechanical or physiological performance, this subscale captures relational closeness during sexual activity (Item 14), satisfaction with the sexual partnership as a whole (Item 15), and overall satisfaction with one’s personal sex life (Item 16). This construct accounts for cognitive appraisals of sexual intimacy, relational quality, and subjective pleasure.

5.6. Pain / Discomfort (Items 17, 18, and 19)

The Pain domain assesses nociceptive, defensive, or distressing physical sensations associated with vaginal penetration. Items evaluate the frequency of pain during vaginal penetration (Item 17), the frequency of pain following coital penetration (Item 18), and the overall severity or intensity of pain experienced during or after intercourse (Item 19). In the scoring scheme, lower raw numbers denote higher pain frequency and severity, which are subsequently reverse-coded to align with the rest of the scale (where lower total domain scores denote greater clinical dysfunction). This construct maps directly to dyspareunia, vaginismus, and the contemporary DSM-5 diagnosis of Genito-Pelvic Pain/Penetration Disorder (GPPPD).

6. Theoretical Framework

The psychometric architecture of the FSFI is deeply embedded in the historical evolution of sexual response theory, reflecting both classical linear physiological models and contemporary circular, biopsychosocial frameworks.

6.1. Classical Linear Models: Masters & Johnson and Kaplan

The structural foundation of the FSFI traces back to the pioneering laboratory investigations of William Masters and Virginia Johnson (1966), who formulated the four-phase Human Sexual Response Cycle consisting of Excitement, Plateau, Orgasm, and Resolution (the EPOR model). Masters and Johnson established the primary physiological markers of female response, notably pelvic vasocongestion (lubrication) and rhythmic neuromuscular platform contractions (orgasm). Subsequently, Helen Singer Kaplan (1979) refined this framework by proposing the Triphasic Model of Sexual Response, introducing Desire as a distinct, brain-mediated neuroendocrine phase preceding autonomic physiological excitement, followed by Orgasm. The DSM-III through DSM-IV-TR diagnostic systems codified Kaplan’s triphasic paradigm into clear psychiatric diagnostic categories: Hypoactive Sexual Desire Disorder, Female Sexual Arousal Disorder, and Female Orgasmic Disorder.

The FSFI operationalizes this triphasic conceptualization by dedicating distinct, independent subscales to Desire, Arousal, Lubrication (representing the physiological excitement component of Masters & Johnson), and Orgasm, alongside a dedicated Dyspareunia/Pain domain.

6.2. Non-Linear and Biopsychosocial Reformulations: Basson’s Model

Despite the utility of linear formulations, empirical sexuality research demonstrated that female sexual response frequently deviates from a strict, sequential progression from spontaneous desire to orgasm. Rosemary Basson (2000, 2001) posited an alternative, Circular Model of Female Sexual Response. Basson emphasized that many women, particularly those in long-term relationships, initiate or engage in sexual interactions not from spontaneous intrinsic desire, but from a baseline of sexual neutrality. Driven by non-sexual motivations—such as emotional intimacy, closeness, affection, or partner receptivity—adequate sexual stimulation subsequently generates subjective arousal and reciprocal responsive sexual desire, culminating in emotional and physical satisfaction, which reinforces sexual motivation.

The FSFI incorporates elements of Basson’s model through two deliberate structural designs. First, it separates subjective mental arousal (Items 3–6) from peripheral somatic lubrication (Items 7–10), acknowledging the phenomenon of subjective-genital desynchrony commonly documented in women. Second, it includes a dedicated Sexual Satisfaction domain that assesses emotional closeness and overall life satisfaction, capturing the emotional rewards that Basson identified as essential for sustaining the feedback loops of sexual well-being.

7. Validity

The FSFI has undergone extensive empirical validation across multiple international clinical and community cohorts, confirming its construct, convergent, discriminant, and criterion-related validity.

7.1. Discriminant Validity

In the initial psychometric validation by Rosen et al. (2000), the FSFI demonstrated robust discriminant validity by significantly distinguishing between sexually functional control women (n = 131) and women clinically diagnosed with female sexual arousal disorder (FSAD; n = 127). Statistically significant differences (p < 0.001) were observed across every individual domain and in the total composite score. Sexually functional controls displayed markedly higher scores (indicating superior function) across Desire (mean = 4.26 vs. 2.73), Arousal (mean = 5.12 vs. 2.65), Lubrication (mean = 5.48 vs. 2.67), Orgasm (mean = 5.14 vs. 2.67), Satisfaction (mean = 5.09 vs. 2.65), and Pain (mean = 5.56 vs. 2.88). Subsequent studies by Wiegel, Meston, and Rosen (2005) replicated these findings in cohorts presenting with Hypoactive Sexual Desire Disorder (HSDD), Female Orgasmic Disorder (FOD), and Dyspareunia/Vaginismus, confirming the instrument’s capacity to discriminate across varied FSD diagnoses.

7.2. Convergent and Criterion Validity

Convergent validity has been established by correlating FSFI domain and total scores with validated legacy measures of marital adjustment, sexual satisfaction, and sexual distress:

• Locke-Wallace Marital Adjustment Test (LWMAT): Significant positive correlations were documented between the FSFI Satisfaction domain and the LWMAT (r = 0.53 to 0.68, p < 0.001), corroborating the association between relationship satisfaction and sexual functioning.
• Female Sexual Distress Scale (FSDS): In validation trials by Derogatis et al. (2002, 2008), FSFI scores demonstrated strong inverse correlations with FSDS scores (r = -0.56 to -0.74, p < 0.001), verifying that lower FSFI functional scores correlate with higher sex-related personal distress.
• Brief Index of Sexual Functioning for Women (BISF-W): Meston (2003) confirmed high convergent validity between corresponding subscales of the BISF-W and FSFI, with domain correlations ranging from r = 0.51 to 0.79.

7.3. Clinical Cutoff Score and Diagnostic Accuracy

In a landmark receiver operating characteristic (ROC) analysis conducted by Wiegel et al. (2005) involving 563 women (comprising both clinical FSD patients and asymptomatic controls), a total FSFI score of 26.55 was identified as the optimal diagnostic cutoff. A score of ≤ 26.55 yielded an overall sensitivity of 77.4% to 88.0% and a specificity of 78.4% to 89.0% for classifying women with sexual dysfunction across multiple diagnostic subtypes. Consequently, an FSFI score below 26.55 is universally recognized as the threshold indicating risk of female sexual dysfunction.

8. Reliability

The FSFI exhibits robust reliability, demonstrating high internal consistency across all subscales and excellent temporal stability across repeated administrations.

8.1. Internal Consistency

In the original normative sample of Rosen et al. (2000), Cronbach’s alpha coefficients for the six domains and the total scale were evaluated independently within both the clinical (FSAD) cohort and the non-clinical control cohort:

• Desire: Clinical α = 0.89; Control α = 0.92
• Arousal: Clinical α = 0.95; Control α = 0.95
• Lubrication: Clinical α = 0.94; Control α = 0.96
• Orgasm: Clinical α = 0.89; Control α = 0.92
• Satisfaction: Clinical α = 0.82; Control α = 0.89
• Pain: Clinical α = 0.92; Control α = 0.94
• Total Scale: Clinical α = 0.97; Control α = 0.97

These values comfortably exceed the conventional psychometric threshold of α ≥ 0.70 for research instruments and α ≥ 0.90 for clinical diagnostic tools, demonstrating negligible measurement error across all six constructs.

8.2. Test-Retest Reliability

Temporal stability was established by Rosen et al. (2000) using a test-retest design across a 2- to 4-week interval in a stable sub-sample of participants. Pearson product-moment correlation coefficients between Time 1 and Time 2 administrations confirmed high stability across all domains: Desire (r = 0.78), Arousal (r = 0.86), Lubrication (r = 0.85), Orgasm (r = 0.83), Satisfaction (r = 0.79), Pain (r = 0.88), and Total Score (r = 0.88; all p < 0.001). Intraclass Correlation Coefficients (ICC) computed in subsequent clinical trials have confirmed these estimates, with ICC values regularly falling between 0.81 and 0.91.

9. Factor Analysis

The latent structural integrity of the FSFI has been rigorously evaluated using both Exploratory Factor Analysis (EFA) and Confirmatory Factor Analysis (CFA).

9.1. Exploratory Factor Analysis (EFA)

During the scale development phase, Rosen et al. (2000) subjected the 19 candidate items to Principal Component Analysis (PCA) with both orthogonal (Varimax) and oblique (Promax) rotations using baseline data from 258 women. A six-factor solution emerged, accounting for 82.7% of the total variance. The six empirically derived components corresponded to the theoretically anticipated clinical domains: Desire, Arousal, Lubrication, Orgasm, Satisfaction, and Pain. All 19 items exhibited strong, clean primary factor loadings (> 0.60) on their respective latent dimensions, with minimal cross-loadings (< 0.30) on secondary factors. The factor pattern matrix demonstrated clear simple structure:

• Items 1 and 2 loaded uniquely onto the Desire factor (loadings of 0.85 and 0.89).
• Items 3, 4, 5, and 6 loaded onto the Arousal factor (loadings ranging from 0.74 to 0.84).
• Items 7, 8, 9, and 10 loaded onto the Lubrication factor (loadings ranging from 0.79 to 0.89).
• Items 11, 12, and 13 loaded onto the Orgasm factor (loadings ranging from 0.77 to 0.86).
• Items 14, 15, and 16 loaded onto the Satisfaction factor (loadings ranging from 0.71 to 0.83).
• Items 17, 18, and 19 loaded onto the Pain factor (loadings ranging from 0.84 to 0.91).

9.2. Confirmatory Factor Analysis (CFA)

Subsequent psychometric evaluations performed structural equation modeling to confirm the six-factor construct. Wiegel, Meston, and Rosen (2005) conducted CFA across both non-clinical control populations and discrete FSD clinical subgroups. The six-factor model exhibited superior fit relative to alternative unidimensional, two-factor (desire/arousal vs. others), or three-factor models. Structural fit indices consistently satisfied contemporary criteria for adequate-to-excellent model fit:

• Comparative Fit Index (CFI): 0.95 to 0.98
• Tucker-Lewis Index (TLI): 0.94 to 0.97
• Root Mean Square Error of Approximation (RMSEA): 0.048 to 0.062 (90% CI: [0.038, 0.069])
• Standardized Root Mean Square Residual (SRMR): 0.035 to 0.046

Although inter-factor correlations between the latent dimensions of Arousal and Lubrication are high (often r > 0.80), structural models specifying them as separate factors maintain significantly better fit than models that collapse them into a single domain. This statistical separation validates the theoretical distinction between central-subjective arousal and peripheral-somatic vasocongestive response.

10. Instrument / Measurement Tool

The FSFI is structured as follows:

• Target Population: Adult females (sexually active or non-active; although specific scoring caveats apply to inactive respondents).
• Administration Format: Self-administered questionnaire (paper-and-pencil, digital/web-based, or mobile interface).
• Administration Time: Approximately 5 to 10 minutes.
• Recall Period: The preceding 4 weeks (“Over the past 4 weeks”).
• Number of Items: 19 items.
• Response Scales: Items utilize 5-point Likert scales (rated 1 to 5) or 6-point scales (rated 0 to 5). Items 1, 2, 15, and 16 are rated on a 1 to 5 scale. Items 3 through 14 and 17 through 19 include an explicit score option of 0 = “No sexual activity” or 0 = “Did not attempt intercourse”.
• Scoring and Weighting System: The total score is computed in a two-stage mathematical procedure: summing raw item scores within each domain, and then multiplying that raw domain sum by a predetermined factor weight.

10.1. Mathematical Scoring Matrix

10.2. Interpretation and Diagnostic Cutoff

• Total Score Range: 2.0 to 36.0 (higher scores reflect superior sexual function, less distress, and absence of pain).
• Clinical Cutoff: A total score of ≤ 26.55 indicates sexual dysfunction and warrants clinical evaluation.
• Sexually Inactive Women (The “Zero Score” Limitation): Respondents reporting zero sexual activity in items containing the “0” option receive a domain score of 0.0 for that subscale, which artificially depresses the full-scale score below the 26.55 threshold. Researchers and clinicians must evaluate whether a score ≤ 26.55 reflects functional sexual distress or simply absence of sexual partnership/activity.

11. Permissions & Fee and Test Year

The Female Sexual Function Index was first published in 2000. The copyright for the FSFI is held by the original authors and the FSFI advisory board. The scale is freely accessible and available without licensing fees for individual clinical use, non-profit healthcare assessment, and non-commercial academic research.

For funded industry clinical trials, corporate research, or incorporation into commercial electronic clinical outcome assessment (eCOA/ePRO) software systems, formal permission, licensing agreements, and certification of linguistic validations must be obtained. Details regarding licensing protocols, certified international language translations, and administrative guidelines are available at the official instrument resource portal (www.fsfiquestionnaire.com) or via correspondence with the copyright holders.

12. References

• Basson, R. (2000). The female sexual response: A different model. Journal of Sex & Marital Therapy, 26(1), 51–65. https://doi.org/10.1080/009262300278641
• Basson, R. (2001). Human sex-response cycles. Journal of Sex & Marital Therapy, 27(1), 33–43. https://doi.org/10.1080/00926230152035831
• Derogatis, L. R., Rosen, R., Leiblum, S., Burnett, A., & Heiman, J. (2002). The Female Sexual Distress Scale (FSDS): Initial validation of a measure of sexual distress for women with female sexual arousal disorder. Journal of Sex & Marital Therapy, 28(4), 317–330. https://doi.org/10.1080/009262302760328253
• Derogatis, L., Clayton, A., Lewis-D’Agostino, D., Wunderlich, G., & Fu, Y. (2008). Validation of the Female Sexual Distress Scale-Revised (FSDS-R) in women with hypoactive sexual desire disorder. The Journal of Sexual Medicine, 5(2), 357–364. https://doi.org/10.1111/j.1743-6109.2007.00672.x
• Kaplan, H. S. (1979). Disorders of Sexual Desire and Other New Concepts and Techniques in Sex Therapy. Brunner/Mazel.
• Masters, W. H., & Johnson, V. E. (1966). Human Sexual Response. Little, Brown and Company.
• Meston, C. M. (2003). Validation of the Female Sexual Function Index (FSFI) in women with female orgasmic disorder and female sexual arousal disorder. Journal of Sex & Marital Therapy, 29(1), 39–46. https://doi.org/10.1080/713847100
• Meyer-Bahlburg, H. F., & Dolezal, C. (2007). The Female Sexual Function Index: A methodological critique and suggestions for improvement. Journal of Sex & Marital Therapy, 33(3), 217–224. https://doi.org/10.1080/00926230701267852
• Rosen, R., Brown, C., Heiman, J., Leiblum, S., Meston, C., Shabsigh, R., Ferguson, D., & D’Agostino, R., Jr. (2000). The Female Sexual Function Index (FSFI): A multidimensional self-report instrument for the assessment of female sexual function. Journal of Sex & Marital Therapy, 26(2), 191–208. https://doi.org/10.1080/009262300278597
• Wiegel, M., Meston, C., & Rosen, R. (2005). The Female Sexual Function Index (FSFI): Cross-validation and development of clinical cutoff scores. Journal of Sex & Marital Therapy, 31(1), 1–20. https://doi.org/10.1080/00926230590475206

13. Items of the Scale (Questionnaire)